We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Biomarker Discovered for Uterine Cancer

By LabMedica International staff writers
Posted on 05 May 2015
A new biomarker has been discovered which makes it possible to identify women with uterine cancer who have a high risk of recurrence.

Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North America and the treatment primarily consists of removing the uterus and in some cases offering chemotherapy if the risk of recurrence is deemed high. More...


Scientists at Uppsala University (Sweden) and their colleagues conducted a study based on samples collected from 500 women who were diagnosed with uterine cancer between the years 1981 and 2007. Tissue microarrays (TMA) were constructed from formalin-fixed, paraffin-embedded (FFPE) primary tumors derived from hysterectomy specimens. Duplicate 1.0 mm diameter cores from each donor block were assembled into a recipient TMA block using the Beecher Manual Tissue Arrayer MTA-1 (Estigen OÜ; Tartu, Estonia).

Automated immunohistochemistry (IHC) was performed using a LabVision Autostainer 480S (Thermo Fisher Scientific; Runcorn, UK). Stained slides were scanned using an Aperio ScanScope XT Slide Scanner (Aperio Technologies; Vista, CA, USA). The l-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated. The protein ASRGL1 is an enzyme that normally exists in healthy cells of the uterus.

The investigators found that patients who had entirely or partially lost ASRGL1 in the tumor cells had a much higher risk of the cancer recurring and dying from the disease, while patients with sustained high levels of ASRGL1 had a much lower risk of recurrence. The study also shows that ASRGL1 is an independent prognostic factor, even after compensating for other risk factors such as tumor stage and tumor grade.

Per-Henrik Edqvist, PhD, the lead author of the study, said, “'I view the results as a first step towards personal treatment of uterine cancer. Today, 10% to 15% of the patients suffer recurrences, even though they were considered low risk patients according to classic diagnostics. By using ASRGL1, the chance of identifying such hidden high-risk patients and offer them more aggressive treatment after their operation increases.” The study was published on April 6, 2015, in the journal Gynecologic Oncology.

Related Links:

Uppsala University
Estigen
Thermo Fisher Scientific
Aperio Technologies



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.